Eurofins BioPharma Services Newsletter 43 - Spring 2026
ARTICLES:
- Advancing AAV therapies to regulatory approval - Eurofins BPT supports methods for EU release
- Viral safety 2.0 - the power of next-generation sequencing
- Eurofins PSS and BPT deliver integrated EM/UM support across all phases
- How will ISO 10993-1:2025 affect the future of preclinical medical device compliance?
- Eurofins generates unique integrated capabilities offer to support clients’ biologics advancements
- Strategy Beyond the Bench: Eurofins launches new U.S. consulting chapter in MedTech strategy & policy
Download the PDF version of pharma newsletter N°43